Glenmark Pharmaceuticals Share Price
2437.20-21.80 (-0.89%)
+21.59% past 1 Year
Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The Company
Corporate filings & documents
Announcements
Glenmark Pharmaceuticals Inc. USA launches Calcium Gluconate Injection USP 1 000 mg/10 mL (100 mg/mL) 5 000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10 000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package
2 weeks agoGlenmark Pharmaceuticals Inc. USA launches Calcium Gluconate Injection USP 1 000 mg/10 mL (100 mg/mL) 5 000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10 000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package
2 weeks agoGlenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray 0.05 mg (50 mcg)/spray
2 weeks agoGlenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray 0.05 mg (50 mcg)/spray
2 weeks agoNewspaper Advertisement regarding the 48th Annual General Meeting ("AGM") to be held on Friday September 11 2026 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")
2 weeks agoNewspaper Advertisement regarding the 48th Annual General Meeting ("AGM") to be held on Friday September 11 2026 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")
2 weeks agoLetter to Shareholders whose email address are not registered providing the web link of Annual Report
3 weeks agoLetter to Shareholders whose email address are not registered providing the web link of Annual Report
3 weeks agoPlease find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26
3 weeks agoPlease find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26
3 weeks agoPlease find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.
3 weeks agoPlease find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.
3 weeks agoPlease find attached Notice of 48th Annual General Meeting for the Financial Year 2025-26
3 weeks agoPlease find attached Notice of 48th Annual General Meeting for the Financial Year 2025-26
3 weeks agoSettlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015
3 weeks agoIntimation of Allotment of shares under the Employee Stock Option Plan 2016
3 weeks agoIntimation of Allotment of shares under the Employee Stock Option Plan 2016
3 weeks agoIntimation of Schedule of Analyst / Institutional Investor Meetings
4 weeks agoIntimation of Schedule of Analyst / Institutional Investor Meetings
4 weeks agoNewspaper Advertisement regarding the 48th Annual General Meeting ("the AGM") to held through Video Conferencing ("VC")/ Other Audio-Visual Means ("OAVM")
4 weeks agoNewspaper Advertisement regarding the 48th Annual General Meeting ("the AGM") to held through Video Conferencing ("VC")/ Other Audio-Visual Means ("OAVM")
4 weeks agoTranscript of the Earnings Call
1 month agoTranscript of the Earnings Call
1 month agoAudio recording of Q1 FY 2026-27 Earnings Call held on August 03 2026
1 month agoAudio recording of Q1 FY 2026-27 Earnings Call held on August 03 2026
1 month agoThe Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended June 30 2026 have been published in Financial Express and Loksatta newspapers on Saturday August 1 2026.
1 month agoThe Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended June 30 2026 have been published in Financial Express and Loksatta newspapers on Saturday August 1 2026.
1 month agoInvestor Presentation - Q1 FY 26-27
1 month agoInvestor Presentation - Q1 FY 26-27
1 month agoPlease find attached Press Release and Management Discussion & Analysis for the first quarter ended June 30 2026
1 month agoPlease find attached Press Release and Management Discussion & Analysis for the first quarter ended June 30 2026
1 month agoPlease find attached Companys officials authorised for the purpose of determining materiality of an event or information and making disclosures to the Stock Exchanges
1 month agoPlease find attached Companys officials authorised for the purpose of determining materiality of an event or information and making disclosures to the Stock Exchanges
1 month agoIntimation of Record Date for Dividend
1 month agoIntimation of Record Date for Dividend
1 month agoThe Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30 2026
1 month agoThe Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30 2026
1 month agoGlenmark Pharmaceuticals Inc. USA launches Sugammadex Injection 200 mg/2mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
1 month agoGlenmark Pharmaceuticals Inc. USA launches Sugammadex Injection 200 mg/2mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
1 month agoNewspaper advertisement for transfer of shares to IEPF Authority
1 month agoNewspaper advertisement for transfer of shares to IEPF Authority
1 month agoIntimation of Earnings Call
1 month agoIntimation of Earnings Call
1 month agoGlenmark receives U.S. FDA approval to expand the use of RYALTRIS Nasal Spray for Children aged 6 to less than 12 years
1 month agoGlenmark receives U.S. FDA approval to expand the use of RYALTRIS Nasal Spray for Children aged 6 to less than 12 years
1 month agoGlenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 inter alia to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter ended June 30 2026
1 month agoGlenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 inter alia to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter ended June 30 2026
1 month agoGlenmark Pharmaceuticals Inc. USA launches Olanzapine for Injection 10 mg/vial Single - Dose Vial
2 months agoGlenmark Pharmaceuticals Inc. USA launches Olanzapine for Injection 10 mg/vial Single - Dose Vial
2 months agoGlenmark advances Multi-Country Phase 3 Clinical Trial of Trastuzmab rezetecan in Platinum-Resistant Ovarian Cancer
2 months agoConcalls & investor presentations
Aug 2026
ConcallPresentation
Jul 2026
ConcallPresentation
Jun 2026
ConcallPresentation
May 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Jan 2026
ConcallPresentation
Aug 2025
ConcallPresentation
Aug 2025
ConcallPresentation
May 2025
ConcallPresentation
May 2025
ConcallPresentation
Feb 2025
ConcallPresentation
Feb 2025
ConcallPresentation
Nov 2024
ConcallPresentation
Nov 2024
ConcallPresentation
Aug 2024
ConcallPresentation
Aug 2024
ConcallPresentation
May 2024
ConcallPresentation
May 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Nov 2023
ConcallPresentation
Nov 2023
ConcallPresentation
Aug 2023
ConcallPresentation
Aug 2023
ConcallPresentation
May 2023
ConcallPresentation
May 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Nov 2022
ConcallPresentation
Aug 2022
ConcallPresentation
Aug 2022
ConcallPresentation
May 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Nov 2021
ConcallPresentation
Aug 2021
ConcallPresentation
May 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Nov 2020
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-08-31
Dividend
2.5
2025-10-03
Dividend
2.5
2025-09-15
Dividend
2.5
2024-09-13
Dividend
2.5
2023-09-18
Dividend
2.5
2022-09-12
Dividend
2.5
2021-09-08
Dividend
2.5
2020-09-17
Dividend
2.5
2019-09-19
Dividend
2.0
2018-09-19
Dividend
2.0
2017-09-20
Dividend
2.0
2016-08-03
Dividend
2.0
2015-09-10
Dividend
2.0
2014-07-10
Dividend
2.0
2013-07-18
Dividend
2.0
2012-07-19
Dividend
2.0
2011-07-28
Dividend
0.4
2010-09-16
Dividend
0.4
Company details
Registered office
B/2 Mahalaxmi Chambers 22 Bhulabhai Desai Road Mumbai Maharashtra PIN: 400026 Tel No: 022 40189999 Fax No: 022 40189988 Email: [email protected] Internet: www.glenmarkpharma.com
Registrars
Karvy Selenium Tower B, Plot 31-32Gachibowli,Financial District, NanakramgudaHyderabad – 500032Tel. No. 040 67161500Fax. No. 040 23001153E-mail: [email protected]: www.karvy.comToll Free No. of exclusive Call Centre:1-800-345001 Karvy Selenium Tower B, Plot 31-32 Gachibowli,Financial District Nanakramguda PIN: Tel No: 040 - 67162222/18003094001 Fax No: NULL Email: [email protected] Internet: www.kfintech.com
Management
Rashmi Khandelwal, Company Secretary & Compliance Officer
Glenn Saldanha, Chairman & Managing Director
Glenn Saldanha, Chairman & Managing Director
Anurag Mantri, Whole Time Director & Global Chief Financial Officer
Cherylann Pinto, Whole Time Director & Corporate Services
B E Saldanha, Promoter & Non-Executive Director
Saira Ramasastry, Non Executive Independent Director
Vijayalakshmi Iyer, Non Executive Independent Director
Dipankar Bhattacharjee, Non Executive Independent Director
Patricia Andrews, Non Executive Independent Director
Pradeep Kumar Sinha, Non Executive Independent Director
Details
BSE 532296
NSE GLENMARK
ISIN INE935A01035